GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (FRA:DYF1) » Definitions » Cyclically Adjusted Price-to-FCF

Dynavax Technologies (FRA:DYF1) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dynavax Technologies Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Dynavax Technologies Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Dynavax Technologies's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Cyclically Adjusted Price-to-FCF Chart

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dynavax Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dynavax Technologies's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Cyclically Adjusted Price-to-FCF falls into.



Dynavax Technologies Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Dynavax Technologies's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Dynavax Technologies's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.123/131.7762*131.7762
=-0.123

Current CPI (Mar. 2024) = 131.7762.

Dynavax Technologies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.648 100.560 -0.849
201409 -0.690 100.428 -0.905
201412 -0.534 99.070 -0.710
201503 -0.845 99.621 -1.118
201506 -0.748 100.684 -0.979
201509 -0.624 100.392 -0.819
201512 -0.686 99.792 -0.906
201603 -0.694 100.470 -0.910
201606 -0.641 101.688 -0.831
201609 -0.690 101.861 -0.893
201612 -0.677 101.863 -0.876
201703 -0.570 102.862 -0.730
201706 -0.312 103.349 -0.398
201709 -0.251 104.136 -0.318
201712 -0.250 104.011 -0.317
201803 -0.529 105.290 -0.662
201806 -0.476 106.317 -0.590
201809 -0.500 106.507 -0.619
201812 -0.490 105.998 -0.609
201903 -0.705 107.251 -0.866
201906 -0.596 108.070 -0.727
201909 -0.377 108.329 -0.459
201912 -0.266 108.420 -0.323
202003 -0.383 108.902 -0.463
202006 -0.205 108.767 -0.248
202009 -0.213 109.815 -0.256
202012 -0.123 109.897 -0.147
202103 0.269 111.754 0.317
202106 0.766 114.631 0.881
202109 0.455 115.734 0.518
202112 0.552 117.630 0.618
202203 -0.315 121.301 -0.342
202206 0.087 125.017 0.092
202209 0.402 125.227 0.423
202212 0.207 125.222 0.218
202303 0.192 127.348 0.199
202306 0.166 128.729 0.170
202309 0.187 129.860 0.190
202312 0.085 129.419 0.087
202403 -0.123 131.776 -0.123

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dynavax Technologies  (FRA:DYF1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Dynavax Technologies Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (FRA:DYF1) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Dynavax Technologies (FRA:DYF1) Headlines

No Headlines